Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.82 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.82 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.82 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998951 | 1.00 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL16922125 | 1.00 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13250907 | 0.94 | OPRM1 (0.84) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL2638139 | 0.93 | OPRD1 (0.79) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL16183153 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL10381363 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL16922130 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL16922136 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL35150 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL13998950 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | DURECT CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-12433877-B2 | Sustained release drug delivery systems and related methods | DURECT CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250262218-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATION | Auros Pharma LLC | 2025-08-21 | — | — | US | disclosed |
| WO-2010132570-A1 | SYNTHESIS OF MORPHINE AND RELATED DERIVATIVES | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7465797-B2 | 6-monoacetylmorphine derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070191595-A1 | 6-MONOACETYLMORPHINE DERIVATIVES USEFUL IN IMMUNOASSAY | GHOSHAL MITALI | 2007-08-16 | — | — | US | disclosed |
| EP-1810973-A1 | 6-monoacetylmorphine derivatives useful in immunoassay | Roche Diagnostics GmbH (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-7238791-B1 | 6-monoacetylmorphine derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142628-A1 | 6-Monoacetylmorphine derivatives useful in immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-6887999-B1 | Preparation of dihydrocodeine from codeine | ACURA PHARMACEUTICALS, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | GUILFORD PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| EP-0388125-A1 | Medicament | BEECHAM GROUP PLC (GB) | 1990-09-19 | — | — | EP | disclosed |
| US-4798792-A | STREPTOMYCES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 2/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | OPRM1 6/4885OPRK1 7/4885OPRD1 4/4885 |
| US-20070191595-A1 | 6-MONOACETYLMORPHINE DERIVATIVES USEFUL IN IMMUNOASSAY | OPRM1, MAG, IL6ST | OPRM1 1/4885OPRK1 24/4885OPRD1 67/4885 |
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | SLC10A2, OPRK1, HBB | OPRM1 5/4885OPRK1 2/4885OPRD1 63/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRM1 4810/4885OPRK1 2862/4885OPRD1 4518/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRK1 2/4885OPRD1 1/4885 |
| US-20070142628-A1 | 6-Monoacetylmorphine derivatives useful in immunoassay | OPRM1, MAG, IL6ST | OPRM1 1/4885OPRK1 24/4885OPRD1 67/4885 |
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | OPRL1, OPRK1, ACHE | OPRM1 8/4885OPRK1 2/4885OPRD1 40/4885 |
| US-12433877-B2 | Sustained release drug delivery systems and related methods | OPRM1, OPRK1, SLC7A5 | OPRM1 1/4885OPRK1 2/4885OPRD1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.